Krystal Biotech (KRYS) recently reported impressive second-quarter earnings for 2026, with a net income of $54.77 million and earnings per share of $1.85. Despite a strong year-to-date share price performance of 34.81%, the stock experienced an 8.41% decline over the last 30 days. Analysts suggest Krystal is currently undervalued with a fair value of $361.67, while a different model estimates a higher valuation of $1,044.39 per share. The company’s future revenue growth will depend on the success of its pipeline expansions and upcoming clinical results, particularly for its major product, VYJUVEK.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-earnings-and-pipeline-progress-put-valu
